TREM2 and lung cancer: In 2016, Yao et al. demonstrated that TREM-2 might act as a negative immunoregulatory molecule through the Syk (spleen tyrosine kinase) pathway in an IL-10-dependent manner and partially predict prognosis in patients with lung cancer [46].